Similarly, the phase III COLUMBUS trial illustrated benefits in terms of PFS and OS in the combination of encorafenib with binimetinib compared with vemurafenib when treating patients who were BRAF‐V600E mutant melanoma and were treatment naïve or progressed on or after first‐line immunotherapy. Here, BRAF is linked to melanoma.